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THREE YEARS OF NICE SCIENTIFIC ADVICE: COMPREHENSIVE ANALYSIS OF
REQUESTS TO THE PROGRAMME
Phillips S1, Crowe E2, Chivers R1, Longson C1
1National Institute for Health and Clinical Excellence, Manchester, UK, 2National Institute for
Health and Clinical Excellence, London, UK
OBJECTIVES:The NICE Scientific Advice (SA) programme was established in 2009. It
provides written advice to pharmaceutical companies and device manufacturers
about development plans for their products to ensure they produce relevant evi-
dence for future submission to NICE. Herein we present a detailed analysis of the
NICE SA programme over the past three years. METHODS: The NICE SA process
involves assessment of the manufacturer’s briefing book with input from external
clinical experts, health economists and methodological experts. Following a face-
to-face meeting between the manufacturer, the expert panel and the SA technical
team, a formal written report summarising the advice is produced. In addition,
NICE SA provides advice alongside the European Medicines Agency (EMA) and
other Health Technology Assessment (HTA) agencies. Whilst such collaborations
do not include a formal written report, advice is given verbally at joint meetings.
Following these meetings, NICE SA provides a commentary on the manufacturer’s
minutes, clarifying the issues identified from the perspective of NICE. RESULTS: To
date the programme has successfully completed 52 formal written advice projects.
Requests for advice alongside the EMA and other HTA agencies have been steadily
increasing with 13 projects completed since 2010. We produced detailed analyses
of all requests to the NICE SA programme to date. Specifically, we will report on the
types of questions posed in manufacturers’ briefing books including questions on
health economic evaluation. We will include a breakdown by therapeutic area,
frequency of requests by company, type of company, profiles of participants at
meetings, and trends over time. CONCLUSIONS:We will reflect on how the various
models of advice projects differ, how manufacturers can get the most from the
process, and how the NICE SA programme is expected to evolve.
NI2
THE USE OF OFF-LABEL COMPARATORS IN NICE APPRAISALS – AN INDIRECT
ENDORSEMENT?
Kusel J, Wong GK
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: NICE has a remit to compare new interventions to the current stan-
dard of care, which could include off-label medication. NICE must also make rec-
ommendations for new interventions within their current marketing authorisa-
tions. The objective was to assess how frequently NICE request off-label
comparators and the implications of this. METHODS: The NICE single technology
appraisal (STA) final scopes from 2010-12 were reviewed. All STAs in development
(as of 13/06/12) that had not been discontinued and had a draft or final scope were
also reviewed. Off-label comparators were identified as those that were being used
outside their license according to the European Medicines Agency or the Electronic
Medicines Compendium. RESULTS: Of 54 completed STAs reviewed, the scopes of
14 (25.9%) requested comparison to at least one off-label comparator. Of these, the
manufacturer performed this comparison in half of the cases. When the manufac-
turer did compare to an off-label comparator, the new intervention was recom-
mended in 4 cases. NICE rejected the other 3 cases for not being cost-effective,
thereby indirectly recommending the off-label alternative. Where the manufac-
turer did not perform the comparison, NICE accepted this decision in 6 (85.7%)
cases, but for the other case the ERG performed additional analysis and found the
new intervention to not be cost-effective when placed ahead of the off-label drug in
the treatment sequence. Again, NICE rejected the new intervention, and indirectly
endorsed use of the off-label comparator. Of the 73 STAs in development, 15 (20.5%)
scopes requested off-label comparators. CONCLUSIONS: NICE have rejected new
interventions in favour of off-label comparators, and given the significant number
of off-label comparators requested in ongoing appraisals they will likely have to
face similar issues in the future. If a new intervention can only be recommended
within its licence but its comparators can be indirectly recommended off-label, this
poses equality questions.
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PATIENT ACCESS SCHEMES IN THE NEW NHS
Spoors J, Brown C, Johnson N, Rietveld A
RJW & Partners, Royston, Hertfordshire, UK
OBJECTIVES: Patient Access Schemes (PAS) have become an integral part of the UK
pharmaceutical environment. The research seeks to investigate the historical role
PAS have played in regard to Health Technology Appraisals (HTAs), how the mech-
anism interacts with other features of the UK funding environment, such as the
Cancer Drugs Fund (CDF), and the PAS strategies employed by pharmaceutical
companies to optimise funding recommendations. It also takes a forward look
towards any role PAS might have in a value-based pricing system, which is poten-
tially facing the UK from 2014. METHODS: We reviewed NICE Technology Apprais-
als which included a PAS from 2002 up to June 2012. We then extracted the key
information and compared and contrasted the advantages/disadvantages of dif-
ferent schemes as time has progressed. RESULTS: PAS have shifted from outcome-
based schemes to financially-based discounts. It is clear from the results that as
PAS have become more integral to the UK HTA environment, an acceptance of
confidentiality and a requirement to prove that PAS reduce uncertainty to payers
are two major developments. The research also highlights how the CDF may act as
a potential disincentive for manufacturers to engage with PAS and provide the NHS
with discounts to achieve cost-effectiveness. CONCLUSIONS: As there are set op-
portunities for manufacturers to submit PAS, it is vital that pharmaceutical com-
panies consider a PAS for the purpose of a HTA as early as possible when bringing
a new product or indication to market. The CDF, whilst expanding medicine access
to patients, may act as a disincentive for pharmaceutical companies to engage with
PAS. With a forward look to 2014, PAS are to remain a vital part of the UK HTA and
payer environment.
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OBJECTIVES: To identify the level of influence of people involved in health tech-
nology assessment (HTA) and drugs’ reimbursement in the UK (with an example of
Alzheimer’s disease) and to gain deeper understanding who these people are and
how they are interconnected within complex HTA network. METHODS: The infor-
mation about members of key national UK HTA agencies (NICE, SMC, AWMSG) was
extracted from the agencies web-sites, supplemented by information from other
sources, and categorized. Next, we analyzed Alzheimer’s disease drugs’ assess-
ments (ten HTAs of donepezil, reminyl, rivastigmine, and memantine published
from 2001 to 2012). The information about people involved in those assessments
was extracted and categorized. A scoring algorithm was developed to calculate
each person’s weight of influence based on a person’s involvement in the assess-
ments and a role within HTA agencies and other organizations. Ni3 visual analysis
software was applied to the dataset to observe and visualize interconnections.
RESULTS: We identified a segment of top influential people within the dataset and
analyzed their interconnections (involvement in multiple assessments, organiza-
tional affiliations). In total 291 people (associated with the agencies or external)
were directly or indirectly involved in HTA process. The majority of these people
(61%) were clinicians whereas 11% and 17% had economic and policy background
respectively. The average score of SMC members’ weight of influence was higher
than NICE members because SMC members were mostly involved in multiple as-
sessments. One individual was identified as connected to three key HTA agencies.
NHS, University of Southampton, University of Glasgow, and NIHR HTA were iden-
tified as key organizations indirectly involved in HTA through their members’
connections. CONCLUSIONS: HTA network is a complex system with many differ-
ent stakeholders. Zooming into this system at the people level allowed deeper
understanding who these people are, how they are interconnected and contribute
to reimbursement decision making process.
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COMPARISON OF CANCER DRUG PRICES IN THE UNITED STATES AND THE UK
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: To understand relative price differential for cancer drugs in the
United States and the UK. Develop implications for pricing strategy and patient
access for cancer drugs. METHODS: Ten branded cancer drugs were selected and
their prices for similar dose and packaging were compared in the United States and
the UK. Prices were analyzed for the end of 2011 and early 2012. Historical exchange
rates were used to convert British pounds to US dollars. Relative price discount was
calculated for all selected cancer drugs. KOLs and payers were interviewed to un-
derstand current and future implications of this price differential. RESULTS: The
median price discount for selected ten branded cancer drugs in the UK versus the
Unitted States was 50%. The range of discount for 10 branded cancer drugs was
27%-61%. The price discount for oral small molecule drugs was higher than for
biologics (55% vs. 45%). Since the UK is one of the few remaining free pricing
markets in Europe, other European markets are likely to have even higher dis-
counts relative to the prices in the United States. Due to rising coinsurance of
speciality products, US cancer patients bear significantly higher cost than patients
in the UK. KOL and payer interviews suggest US pricing trends for cancer drugs are
unlikely to be sustained at this level in the future. CONCLUSIONS: US cancer drug
prices are significantly higher than the prices in the UK. This price differential is
unlikely to be sustained in the future.
PR2
GUIDING PRINCIPLES FOR PROVIDING EFFECTIVE ACCESS TO MEDICINES IN
EMERGING MARKETS
Shankar R, Hickson S
IMS Consulting Group, Cambridge, UK
Chronic and non-communicable diseases are becoming a major health problem in
emerging markets. Access to effective current and pipeline treatments is limited
due to the high cost. Financing solutions will take time as these markets grow and
develop public and private insurance systems. However, governments are faced
with the immediate problem of access to treatments given limited resources. This
paper lays out guiding principles for providing effective access to these treatments
within the budget constraints faced by these governments. We looked at how
mature markets have used HTA and other pricing and market access tools to eval-
uate, prioritise and provide access to treatments. We analyse IMS data on products
launched since 2005 to find that these markets have broadly used three levers to
manage access effectively – time to reimbursement, level of access and price.
Treatments with high value to the broad population have been provided quick
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